An update on the therapeutic potential of calpain inhibitors: a patent review

References

• Guroff G. A neutral, calcium-activated proteinase from the soluble fraction of rat brain. J Bio Chem. 1964;239:149–155.
   PubMed Web of Science ®Google Scholar
• Macqueen DJ, Wilcox AH. Characterization of the definitive classical calpain family of vertebrates using phylogenetic, evolutionary and expression analyses. Open Bio. 2014;4:130–219.
   Web of Science ®Google Scholar
• Villalobo A, González-Muñoz M, Berchtold MW. Proteins with calmodulin-like domains: structures and functional roles. Cell Mol Life Sci. 2019;76:2299–2328.
   PubMed Web of Science ®Google Scholar
• Campbell RL, Davies PL. Structure function relationships in calpains. Biochem J. 2012;447:335–351.
   PubMed Web of Science ®Google Scholar
• Sorimachi H, Mamitsuka H, Ono Y. Understanding the substrate specificity of conventional calpains. Biol Chem. 2012;393:853–871.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Hata S, Kawabata Y, et al. Structure, activation, and biology of calpain. Diabetes. 2004;53(Suppl 1):S12–8.
   PubMedGoogle Scholar
• Davis TL, Walker JR, Finerty PJ, et al. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition. J Mol Biol. 2007;366:216–229.
   PubMed Web of Science ®Google Scholar
• Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nat. 2008;456:409–412.
   Google Scholar
• Ono Y, Saido TC, Sorimachi H. Calpain research for drug discovery: challenges and potential. Nat Rev Drug Dis. 2016;15:854–876.
   PubMed Web of Science ®Google Scholar
• Potz BA, Sabe AA, Abid MR, et al. Calpains and coronary vascular disease. Circ J. 2016;80:4–10. Epub 2015 Oct 21.
   PubMed Web of Science ®Google Scholar
• Baudry M, Chou MM, Bi X. Targeting calpain in synaptic plasticity. Expert Opin Ther Targets. 2013;17:579–592.
   PubMed Web of Science ®Google Scholar
• Zhu G, Liu Y, Wang Y, et al. Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. J Neurosci. 2015;35:621–633.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Saito KI, Grynspan F, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer’s disease. Ann N Y Acad Sci. 1994;747:77–91.
   PubMed Web of Science ®Google Scholar
• Baudry M, Bi X. Calpain-1 and Calpain-2: the Yin and Yang of synaptic plasticity and neurodegeneration. Trends Neurosci. 2016;39:235–245.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bi X, Baudry M. Calpain-2 as a therapeutic target for acute neuronal injury. Expert Opin Ther Targets. 2018;22:19–29.
   PubMed Web of Science ®Google Scholar
• Hoskin V, Szeto A, Ghaffari A, et al. Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. Mol Biol Cell. 2015;26:3464–3479.
   PubMed Web of Science ®Google Scholar
• Grieve S, Gao Y, Hall C, et al. Calpain genetic disruption and HSP90 inhibition combine to attenuate mammary tumorigenesis. Mol Cell Biol. 2016;36:2078–2088.
   PubMed Web of Science ®Google Scholar
• Leloup L, Wells A. Calpains as potential anti-cancer targets. Expert Opin Ther Targets. 2011;15:309–323.
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Mody RK, Walker T, et al. The global burden of fungal diseases. Infect Dis Clin North Am. 2016;30:1–11.
   PubMed Web of Science ®Google Scholar
• Staniec D, Ksiazek M, Thogersen IB, et al. Calcium regulates the activity and structural stability of Tpr, a bacterial calpain-like peptidase. J Biol Chem. 2015;290:27248–27260.
   PubMed Web of Science ®Google Scholar
• Chandramohanadas R, Davis PH, Beiting DP, et al. Apicomplexan parasites co-opt host calpains to facilitate their escape from infected cells. Sci. 2009;324:794–797.
   PubMed Web of Science ®Google Scholar
• Pietsch M, Chua KC, Abell AD. Calpain: attractive targets for the development of synthetic inhibitors. Curr Top Med Chem. 2010;10:270–293.
   PubMed Web of Science ®Google Scholar
• Nikkel AL, Martino B, Markosyan S, et al. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology. 2012;63:606–612.
   PubMed Web of Science ®Google Scholar
• Roudaut C, Roy FL, Suel L, et al. Restriction of calpain 3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation. 2013;128:1094–1104.
   PubMed Web of Science ®Google Scholar
• Gan-Or Z, Bouslam N, Birouk N, et al. Mutations in CAPN1 cause autosomal-recessive hereditary spastic paraplegia. Am J Hum Genet. 2016;98:1038–1046.
   PubMed Web of Science ®Google Scholar
• Tyndall JDA, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem Rev. 2005;105:973–1000.
   PubMed Web of Science ®Google Scholar
• Pehere AD, Abell AD. New β-strand templates constrained by Huisgen cycloaddition. Org Lett. 2012;14:2012.
   Web of Science ®Google Scholar
• Driggers EM, Hale SP, Lee J, et al. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat Rev Drug Dis. 2008;7:608–624.
   PubMed Web of Science ®Google Scholar
• Yudin AK. Macrocycles: lessons from the distant past, recent developments, and future directions. Chem Sci. 2015;6:30–49.
   PubMed Web of Science ®Google Scholar
• Marsault E, Peterson ML. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J Med Chem. 2011;54:1961–2004.
   PubMed Web of Science ®Google Scholar
• Low KE, Ler S, Chen KJ, et al. Rational design of calpain inhibitors based on calpastatin peptidomimetics. J Med Chem. 2016;59:5403–5415.
   PubMed Web of Science ®Google Scholar
• Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. Biol Chem. 2004;385:465–472.
   PubMed Web of Science ®Google Scholar
• Anagli J, Seyfried D. Methods, systems, and compositions for calpain inhibition. US 9,074,019 B2. 2015.
   Google Scholar
• Bartus RT, Hills L, Eveleth DD, et al. Methods of treatment of neurodegeneration with calpain inhibitors. US5444042A. 1995.
   Google Scholar
• Donkor I. An updated patent review of calpain inhibitors (2012−2014). Expert Opin Ther Pat. 2014;25:17–31.
   PubMed Web of Science ®Google Scholar
• Donkor IO. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat. 2011;21:601–636.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Shi J, Dai W. New therapies for reducing post-myocardial left ventricular remodeling. Ann Transl Med. 2015;3:20.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen B, Huang C-K, et al. Targeting calpain for heart failure therapy: implications from multiple murine models. J Am Coll Cardiol Basic Trans Sci. 2018;3:503–517.
   Google Scholar
• Sandmann S, Prenzel F, Shaw L, et al. Activity profile of calpains I and II in chronically infarcted rat myocardium–influence of the calpain inhibitor CAL 9961. Br J Pharmacol. 2002;135:1951–1958.
   PubMed Web of Science ®Google Scholar
• Letavernier E, Zafrani L, Perez J, et al. The role of calpains in myocardial remodeling and heart failure. Cardiovasc Res. 2012;96:38–45.
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Zhang GX, Obata K, et al. Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic arrest. Am J Physiol Heart Circ Physiol. 2010;298:643–651.
   Web of Science ®Google Scholar
• Khalil PN, Neuhofd C, Huss R, et al. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol. 2005;528:124–131.
   PubMed Web of Science ®Google Scholar
• Inserte J, Hernando V, Garcia-Dorado D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovascr Res. 2012;96:23–31.
   PubMed Web of Science ®Google Scholar
• Hernando V, Inserte J, Sartorio CL. Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. J Mol Cell Cardiol. 2010;49:271–279.
   PubMed Web of Science ®Google Scholar
• Garcia Dorado Garcia AD, Inserte I, Poncelas NM Calpain inhibitors in the prevention and/or treatment of ventricular remodeling. US20190125714 A1. 2019.
   Google Scholar
• Ross AC, Xu Y, Lu L, et al. Biosynthetic multitasking facilitates thalassospiramide structural diversity in marine bacteria. J Am Chem Soc. 2013;135:1155–1162.
   PubMed Web of Science ®Google Scholar
• Lu L, Meehan MJ, Gu S, et al. Mechanism of action of thalassospiramides, a new class of calpain inhibitors. Sci Rep. 2015;5:8783–8790.
   PubMed Web of Science ®Google Scholar
• Um S, Pyee Y, Kim E-H, et al. Thalassospiramide G, a new -amino-acid-bearing peptide from the marine bacterium Thalassospira sp. Mar Drugs. 2013;11:611–622.
   PubMed Web of Science ®Google Scholar
• Kaneko I, Minekura H, Takeuchi Y, et al. inventors; Sankyo Co., Ltd, assignee. New compound B1371A or B1371B and their production. Japanese patent JP 06,298,796 (A). 1994 Oct 25.
   Google Scholar
• Osumi H. inventor; Sankyo Co., Ltd. assignee. New compound B1371E or B1371F and their production. Japanese patent JP 08,081,431 (A). 1996 Jun 23.
   Google Scholar
• Tsubuki S, Saito Y, Tomioka M, et al. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem. 1996;119:572–576.
   PubMed Web of Science ®Google Scholar
• Pehere AD, Nguyen S, Garlick SK, et al. Tripeptide analogues of MG132 as protease inhibitors. Bioorg Med Chem. 2019;27:436–441.
   PubMed Web of Science ®Google Scholar
• Meregalli C. An overview of bortezomib-induced neurotoxicity. Toxics. 2015;3:294–303.
   PubMed Web of Science ®Google Scholar
• Pehere AD, Pietsch M, Gutschow M, et al. Synthesis and extended activity of triazole containing macrocyclic protease inhibitors. Chem Eur J. 2013;19:7975–7981.
   PubMed Web of Science ®Google Scholar
• Stracher A, Kesner L, Shulman A. Targeted delivery of pharmaceutical compounds. US Patent 8729024 B2. 2014.
   Google Scholar
• Takahashi Y, Nishimura T, Higuchi K, et al. Transport of pregabalin via L-type amino acid transporter 1 (SLC7A5) in human brain capillary endothelial cell line. Pharm Res. 2018;35:246.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45:13–18.
   PubMed Web of Science ®Google Scholar
• Liu S, Yin F, Zhang J, et al. The role of calpains in traumatic brain injury. Brain Inj. 2014;28:133–137.
   PubMed Web of Science ®Google Scholar
• Dugue R, Hassen GW, Shulman A, et al. Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur. Brain Res Bull. 2018;142:368–373.
   PubMed Web of Science ®Google Scholar
• Stracher A. Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. Ann NY Acad Sci. 1999;884:52–59.
   PubMed Web of Science ®Google Scholar
• Hassen GW, Kesner L, Stracher A, et al. Effects of novel calpain inhibitors in transgenic animal model of Parkinson’s disease/dementia with Lewy bodies. Sci Rep. 2018;8:18083.
   PubMed Web of Science ®Google Scholar
• Wang KK, Nath R, Posner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA. 1996;93:6687–6692.
   PubMed Web of Science ®Google Scholar
• Adams SE, Parr C, Miller DJ, et al. Potent inhibition of Ca2+-dependent activation of calpain-1 by novel mercaptoacrylates. Med Chem Comm. 2012;3:566–570.
   Google Scholar
• Adams SE, Robinson EJ, Miller DJ, et al. Conformationally restricted calpain inhibitors. Chem Sci. 2015;6:6865–6871.
   PubMed Web of Science ®Google Scholar
• Besse D, Siedler F, Diercks T. Kessler H and Moroder L. The redox potential of selenocystine in unconstrained cyclic eptides. Angew Chem Int Ed. 1997;36:883–885.
   Web of Science ®Google Scholar
• Low KE, Partha SK, Davies PL, et al. Allosteric inhibitors of calpains: re-evaluating inhibition by PD150606 and LSEAL. Biochim Biophys Acta. 1840;2014:3367–3373.
   Google Scholar
• Kalash L, Cresser-Brown J, Habchi J, et al. Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space. Eur J Med Chem. 2018;157:1264–1275.
   PubMed Web of Science ®Google Scholar
• Mann E, Chana A, Sanchez-Sancho F, et al. Novel peptide-heterocycle hybrids: synthesis and preliminary studies on calpain inhibition. Adv Syn Catal. 2002;344:855–867.
   Web of Science ®Google Scholar
• Gutierrez S, Moron M, Griera M, et al. Discovery of potent calpain inhibitors based on the azoloimidazolidenone scaffold. Eur J Med Chem. 2018;157:946–959.
   PubMed Web of Science ®Google Scholar
• Moron M, Burgos C, Alvarez-Builla J, et al. A cascade reaction of azolopyrimidines. Synthesis of unusual indole and azaindole derivatives. Chem Commun. 2012;48:9171–9173.
   PubMed Web of Science ®Google Scholar
• Kim D, Dietz HC. Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies. WO 2016/037157 A2. 2016.
   Google Scholar
• Buckman BO, Nicholas JB, Yuan S; Blade Therapeutics, Inc. Calpain modulators and methods of production and use thereof. WO2017156074A1. 2017.
   Google Scholar
• Buckman BO, Nicholas JB, Ma J; Blade Therapeutics, Inc. Calpain modulators and methods of production and use thereof. WO2018236913A1. 2018.
   Google Scholar
• Buckman BO, Nicholas JB, Yuan S, et al.; Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof. US2019/0194139A1. 2019.
   Google Scholar
• Tsuji T, Shimohama S, Kimura J, et al. m-Calpain calcium-activated neutral proteinase) in Alzheimer’s disease brains. Neurosci Lett. 1998;248:109–112.
   PubMed Web of Science ®Google Scholar
• Saito K, Elce JT, Hamos JE, et al. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA. 1993;90:2628–2632.
   PubMed Web of Science ®Google Scholar
• Trinchese F, Fa’ M, Liu S, et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 2008;118:2796–2807.
   PubMed Web of Science ®Google Scholar
• Rao MV, McBrayer MK, Campbell J, et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci. 2014;34:9222–9234.
   PubMed Web of Science ®Google Scholar
• Liang B, Duan B, Zhou X, et al. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737–27744.
   PubMed Web of Science ®Google Scholar
• Granic I, Nyakas C, Luiten PGM, et al. Calpain inhibition prevents amyloid-β-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharm. 2010;59:334–342.
   PubMed Web of Science ®Google Scholar
• Medeiros R, Kitazawa M, Chabrier MA, et al. Calpain inhibitor A-705253 mitigates Alzheimer’s disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 2012;181:616–625.
   PubMed Web of Science ®Google Scholar
• Kling A, Jantos K, Mack H, et al. Discovery of novel and highly selective inhibitors of calpain for the treatment of Alzheimer’s disease: 2-(3-phenyl-1H-pyrazol-1-yl)-nicotinamides. J Med Chem. 2017;60:7123–7138.
   PubMedGoogle Scholar
• ABBVIE INC. Carboxamide compounds and their use as calpain inhibitors V. US 2015/0252017 A1. 2015.
   Google Scholar
• Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010;120:3421–3431.
   PubMed Web of Science ®Google Scholar
• Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta Proteins Proteomics. 2012;1824:68–88.
   PubMed Web of Science ®Google Scholar
• Broemme D, Lecaille F, Cathepsin K. Inhibitors for osteoporosis and potential off-target effects. Expert Opin Invest Drugs. 2009;18:585–600.
   PubMed Web of Science ®Google Scholar
• Kling A, Jantos K, Mack H, et al. Mitigating the metabolic liability of Carbonyl reduction: novel calpain inhibitors with P1′ extension. ACS Med Chem Lett. 2018;9:221–226.
   PubMed Web of Science ®Google Scholar
• Donkor IO, Korukonda R, Huang TL, et al. Peptidyl aldehyde inhibitors of calpain incorporating P2-proline mimetics. Bioorg Med Chem Lett. 2003;13:783–784.
   PubMed Web of Science ®Google Scholar
• Jantos K, Kling A, Mack H, et al. Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. Bioorg Med Chem Lett. 2019;29:1968–1973.
   PubMedGoogle Scholar
• Lon HK, Mendonca N, Goss S, et al. Pharmacokinetics, safety, tolerability, and pharmacodynamics of Alicapistat, a selective inhibitor of human calpains 1 and 2 for the treatment of Alzheimer disease: an overview of Phase 1 studies. Clin Pharmacol Drug Dev. 2019;8:290–293.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kikuchi T, Fukui I, et al. Inactivation of calpain I and calpain II by specificity-oriented tripeptidyl chloromethyl ketones. J Biochem (Tokyo). 1986;99:173–179.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kikuchi T, Yumoto N, et al. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J Biol Chem. 1984;259:12489–12494.
   PubMed Web of Science ®Google Scholar